(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of -10.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Taysha Gene Therapies's revenue in 2024 is $12,873,000.On average, 3 Wall Street analysts forecast TSHA's revenue for 2024 to be $1,695,495,971, with the lowest TSHA revenue forecast at $1,389,515,615, and the highest TSHA revenue forecast at $1,951,060,273. On average, 3 Wall Street analysts forecast TSHA's revenue for 2025 to be $2,107,432,016, with the lowest TSHA revenue forecast at $1,403,861,646, and the highest TSHA revenue forecast at $2,459,319,672.
In 2026, TSHA is forecast to generate $1,733,820,369 in revenue, with the lowest revenue forecast at $1,418,207,678 and the highest revenue forecast at $2,049,433,060.